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Abstract
Background: During human pregnancy, the placental villi produces high amounts of estradiol. This
steroid is secreted by the syncytium, which is directly in contact with maternal blood. Estradiol has to
cross placental foetal vessels to reach foetal circulation. The enzyme 17beta-hydroxysteroid
dehydrogenase type 2 (17beta-HSD2) was detected in placental endothelial cells of foetal vessels inside
the villi. This enzyme catalyzes the conversion of estradiol to estrone, and of testosterone to
androstenedione. It was proposed that estradiol level into foetal circulation could be regulated by 17beta-
HSD2.
Methods: We obtained placentas from 10 to 26 6/7 weeks of pregnancy from women undergoing
voluntary termination of pregnancy, term placentas were collected after normal spontaneous vaginal
deliveries. We quantified 17beta-HSD2 mRNA levels in mid-gestation and term human placenta by RT-
QPCR. We produced a new anti-17beta-HSD2 antibody to study its spatio-temporal expression by
immunohistochemistry. We also compared steroid levels (testosterone, estrone and estradiol) and
17beta-HSD2 mRNA and protein levels between term placenta and endometrium.
Results: High 17beta-HSD2 mRNA and protein levels were found in both mid-gestation and term
placentas. However, we showed that 17beta-HSD2 mRNA levels increase by 2.27 fold between mid-
gestation and term. This period coincides with a transitional phase in the development of the villous
vasculature. In mid-gestation placenta, high levels of 17beta-HSD2 were found in mesenchymal villi and
immature intermediate villi, more precisely in endothelial cells of the stromal channel. At term, high levels
of 17beta-HSD2 were found in the numerous sinusoidal capillaries of terminal villi. 17beta-HSD2 mRNA
and protein levels in term placentas were respectively 25.4 fold and 30 to 60 fold higher than in the
endometrium. Steroid levels were also significantly higher in term placenta than in the endometrium.
Conclusion: The spatial and temporal expression of 17beta-HSD2 in the placenta during pregnancy and
the comparison of 17beta-HSD2 expression and steroid levels between placental villi and endometrium
are compatible with a role in the modulation of active and inactive forms of estrogens. Our observations
strongly support the hypothesis that 17beta-HSD2 acts as a barrier decreasing estradiol secretion rates in
the foetal circulation.
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Background
During human pregnancy, the placenta produces and
secretes high amounts of estradiol (E2) and estrone (E1)
[1,2]. E2, the most potent form, participates in the devel-
opment of some foetal organ systems. Indeed, late in ges-
tation, E2 cooperates in foetal lung maturation by
stimulating Type II pneumocytes differentiation and sur-
factant phospholipid synthesis [3,4]. E2 also participates
in activation of the hypothalamo-hypophyso-adrenal
(HPA) axis [5,6] as well as in maturation of cutaneous
barrier [7,8]. It is also well documented that maternal
blood levels of estrogens rise continuously during all
pregnancy [9-11]. However, the level of E2 in the umbili-
cal vein supplying oxygenated blood to the foetus does
not increase in parallel with that in the maternal vein,
whereas the level of E1 in the umbilical vein continues to
increase during pregnancy [12,13]. These asymmetric
releases of E2 and E1 between foetal and maternal circula-
tion strongly suggest the presence of a mechanism that
controls the amounts of E2 entering into foetal circula-
tion.
17β-hydroxysteroid dehydrogenases (17βHSDs) catalyze
oxidoreduction at position C17 of C18 steroids such as E1
and E2, and C19 steroids (testosterone/androstenedione;
DHEA/androstenediol) and at position C20 of progestins.
The human placenta expresses mainly two 17βHSDs,
types 1 and 2. Type 1 almost exclusively reduces E1 in E2
[14,15], whereas type 2 is reactive with E2 and testoster-
one with nearly comparable activities [16,17]. E2 synthe-
sis in placenta depends on C19 steroid precursors
dehydroepiandrosterone (DHEA) and its sulphate
(DHEAS) from both maternal and foetal adrenal origin
[1,2]. DHEAS is converted to DHEA by the sulfatase, then
into androstenedione by the 3β-HSD type 1 (3β HSD1),
then aromatized in E1 by the cytochrome P450 aromatase
and finally reduced by the 17βHSD type 1 to generate E2.
In human placenta, 17βHSDs type 1 and type 2 are abun-
dantly expressed [18,19]. All the enzymes required in E2
synthesis are exclusively expressed by the syncytial layer
(SL) delineating the floating villi [14,18,20]. E2 is secreted
in both maternal and foetal circulations. However, to
reach the foetus, E2 must inevitably cross the endothe-
lium that forms the wall of the blood vessels. We and oth-
ers [18,21-23] have previously shown that in term
placenta 17βHSD2 mRNA is exclusively expressed in the
endothelial cells (EC) of foetal vessels [18]. In two sepa-
rate ontogeny studies, 17βHSD2 protein was first detected
around weeks 7 [21] or 12 of pregnancy [20]. Then, the
number of 17βHSD2-positive cells increases, reaching a
plateau around week 19 of gestation and staying at that
level until term [14,18,20]. Another study has shown that
17βHSD2 is also detected in the chorionic vein at 19
weeks of pregnancy [22].
During normal placental development, villous trees
expand extensively by sprouting [24]. Between weeks 15
and 21 of pregnancy, three different subtypes of villosities
can be distinguished: the mesenchymal villi (MV), the
immature intermediate villi (IIV) and the stem villi (SV).
The MV is the forerunner of all other types of villi [24] and
is in continuous formation during pregnancy [24,25].
During the first and the second trimesters the MV differen-
tiates into IIV, and then IIV is transformed in SV. The MV
tissue is rich in mesenchymal cells and poor in collagen.
It is composed of loose connective tissues containing only
few capillaries. The IIV also contains loose connective tis-
sues, but is characterized by the presence of many arteri-
oles and venules with only few undilated capillaries and
an abundant stromal channel network [26]. By contrast,
the SV contains a central vessel and is characterized by the
presence of a stroma exhibiting huge and condensed bun-
dles of collagen and by a well-developed paravascular cap-
illary (PC) network beneath the SL [27]. During the last
trimester of pregnancy, the MV differentiates into mature
intermediate villi (MIV), which is then transformed into
terminal villi (TV) [24], an highly efficient structure spe-
cialized in foeto-maternal exchanges. Indeed, TV contains
highly dilated sinusoidal capillaries (Si) constituting
more than 50% of the stromal volume. This the most
abundant type of villi observed at term [25].
In the present study, we have further evaluated the mRNA
and protein expression of the key steroidogenic enzyme
17βHSD2 in various structures of human placenta
obtained at mid and term pregnancy. The levels of
17βHSD2 mRNA in several human placentas collected
during this pregnancy interval have been precisely deter-
mined by real-time quantitative PCR using several house-
keeping genes for data normalization. The protein has
been detected by immunohistochemistry using a novel
and very sensitive anti-17βHSD2 antibody, while the
mRNA was localized by in situ hybridization. 17βHSD2 is
recognized to play a role in the control of E2 levels in the
endometrium [28,29]. To further evaluate the capacity of
17βHSD2 to regulate the amount of E2 entering into foe-
tal circulation, we also have compared steroid levels (tes-
tosterone, estrone and estradiol) and 17βHSD2 mRNA
and protein levels between the endometrium and the pla-
centa. Taken together, our results support an important
role for 17βHSD2 in the mechanisms that control estra-
diol levels in foetal circulation.
Methods
Human tissues
Human placentas from weeks 10 to 24 6/7 of pregnancy
(n = 25) were obtained from women undergoing volun-
tary pregnancy termination. Term placentas (38–41 weeks
of pregnancy, n = 10) were collected after normal sponta-
neous vaginal deliveries. No placenta had histopathologi-Reproductive Biology and Endocrinology 2007, 5:30 http://www.rbej.com/content/5/1/30
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cal abnormality. Endometrial tissues in mid-late secretory
phase were obtained by biopsy. For all patients, informed
consent was obtained according to the policies for the
Human Studies and the Institutional Review Board of the
Centre Hospitalier Universitaire de Québec (protocols no 75-
05-04, 70-05-05, 62-05-13, and 62-05-12). Gestational
age was determined based on bi-parietal and abdominal
diameters, and cephalo-caudal and femur lengths. Tissues
were collected on ice. To avoid contamination of the villi
by decidua or foetal membranes, a 0.5 cm slice of tissue
was removed on each side of the placentas. Then, small
pieces of villi (0.5 cm3) were prepared and extensively
rinsed in PBS. Several pieces were kept frozen until RNA
or protein extraction, while others were fixed in 4% para-
formaldehyde for 24 hours prior processing for routine
paraffin wax embedding. Five μm tissue sections were
used.
Northern blot analysis
Northern blot analysis were performed as described [18].
Briefly, 20 μg of total RNAs were glyoxalized and electro-
phoresed. After Northern blot, membranes were hybrid-
ized at 42°C and washed under high stringency
conditions [18]. The 17βHSD2 full-length cDNA frag-
ment [14], and the gamma-actin cDNA 2 kb fragment
were used to prepare the probes [30].
Real-time quantitative PCR
RNA extraction, cDNA synthesis, and real-time quantita-
tive PCR were performed as described previously [31].
Briefly, total RNA extracts were prepared from 0.5 cm3 pla-
cental samples and then purified on CsCl gradients. A 4 μg
aliquot of total RNA was treated with DNase (DNase I,
0.25 unit/μg of total RNA), and reversed transcribed
(Superscript II, Invitrogen) according to the protocol of
the manufacturer, using hexameric random primer
(pd(N)6, Invitrogen) in a 20 μl final volume. LightCycler-
FastStart DNA Master SYBR Green I kits (Roche) were used
for real-time PCR. Reactions were performed according to
the protocol of the manufacturer with 0.5 μM of each
primer (final concentration), 3 mM MgCl2, and an
amount of cDNA samples corresponding to 100 ng of
total RNA input in a 20 μl final volume. After enzyme acti-
vation (10 min, 95°C), 40 PCR cycles were performed: 0
sec, 95°C; 5 sec annealing temperature (see below); 20
sec, 72°C; 5 sec, temperature of fluorescence intensity
reading (see below). At the end of each run, samples were
heated to 95°C with a temperature transition rate of
0.2°C/sec to construct dissociation curves. Several PCR
reactions were tested on a 2% agarose gel, and amplicons
were subjected to DNA sequencing to confirm the specifi-
city of the PCR reactions. The primers selected for
17βHSD2 encompass more than one intron. Gene/Gen-
Bank accession number/5' oligonucleotide/3' oligonucle-
otide/length of amplicon/annealing temperature/
temperature of fluorescence intensity reading:17βHSD2/
NM_002153/TGTCAGCAGCATGGGAGGAG/CGCCAA-
GATAGCATGCTGGA/346 nt/70°C/84°C; GAPDH/
NM_002046/GAAGACTGTGGATGGCCCCTC/GTTGAG-
GGCAATGCCAGCCCC/358 nt/58°C/88°C; YWHAZ/
NM_003406/AGACGGAAGGTGCTGAGAAA/GAAG-
CATTGGGGATCAAGAA/127 nt/59°C/76°C; TBP/
NM_003194/GAACCACGGCACTGATTTTC/CCCCAC-
CATGTTCTGAATCT/157 nt/58°C/80°C; HPRT1/
NM_000194/TGACACTGGCAAAACAATGCA/GGTC-
CTTTTCACCAGCAAGCT/94 nt/59°C/78°C. A standard
curve for real-time PCR was prepared for each gene using
specific amplicons previously obtained by PCR,
sequenced, and calibrated by electrophoresis on an agar-
ose gel. The program supplied by the manufacturer (Light-
Cycler Software, Version 3.5) was used to import the
standard curves and calculate the amount of PCR prod-
ucts.
Selection of normalization genes
To ensure a more accurate evaluation of the relative
expression of 17βHSD2 mRNA in mid-gestation and term
placentas, we assessed the expression stability of four
housekeeping genes (GAPDH, YWHAZ, TBP, and
HPRT1), based on the approach proposed by Vandesom-
pele [32]. Housekeeping gene expression levels measured
in all samples were evaluated with the geNorm program
[32], which is a Microsoft Excel applet that estimates gene
stability through numerous pair-wise comparisons. Fol-
lowing gene stability analysis, normalization factors were
calculated from the expression levels of the three most sta-
ble housekeeping genes. Those were then used to normal-
ize 17βHSD2 expression levels in the different placental
samples. The same approach was used to determine
housekeeping gene stability between term placentas and
mid-late secretory phase endometrial tissues.
Preparation and characterization of our novel anti-
17βHSD2 polyclonal antibody
Polyclonal antibody against human 17βHSD2
A synthetic peptide (LEKDILDHLPAEVQ) corresponding
to amino acids 279 to 292 of 17βHSD2 was synthesized
by the Service de Protéomique de l'Est du Québec (CHUL
Research Center) using standardized protocol, purified by
HPLC, and coupled to keyhole limpet hemocyanin. A pol-
yclonal anti-17βHSD2 antiserum was developed by
repeated immunization of rabbits. The antiserum was
purified using a sulfoLinK coupling gel (Pierce Biotech-
nology Inc., Rockford, IL).
Tissue fractionation and Western blot analysis
Villous tissues from term pregnancy were first fractionated
in cytosol and microsomes as described previously
[14,18]. Briefly, small pieces of villi were homogenized in
ice-cold buffer containing 40 mM potassium phosphateReproductive Biology and Endocrinology 2007, 5:30 http://www.rbej.com/content/5/1/30
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(pH 7.0), 1.0 mM EDTA, and 20% (vol/vol) glycerol.
Samples were then centrifuged at 1,000 × g for 10 min to
remove cell debris and again at 105,000 × g for 1 h. Super-
natants were saved as cytosol, and pellets as microsomes.
Ten micrograms of each protein sample (cytosol and
microsomes) were separated by SDS-PAGE and trans-
ferred to a nitrocellulose membrane (Bio-RAD). Mem-
branes were blocked overnight at 4°C with 5% (wt/vol)
fat-free dry milk powder in PBS containing 0,05% (vol/
vol) Tween 20. These membranes were then incubated
with our anti-17βHSD2 antibody (1:1000) for 2 hours at
room temperature. After washing, bound antibodies were
visualized with horseradish peroxidase-conjugated goat
anti-rabbit antibodies using a Western Lightning kit (Per-
kin Elmer). An aliquot of the 17βHSD2 antiserum was
pre-incubated at 4°C for 24 h with an excess (10-6M) of
17βHSD2 synthetic peptide used previously to develop
the antibody. This adsorbed antiserum was used as nega-
tive control. The absence of primary antibody was also
tested as negative control.
Two-dimensional gel electrophoresis
Total protein extracts were prepared from small pieces of
term villi. Tissues were homogenized in PBS and then cen-
trifuged 15 min at 250 × g. The pellet was re-suspended in
0.5% Nonidet P-40 in PBS. After a 15 min centrifugation
at 300 × g, 9 volumes of acetone were added to the super-
natant. After a 2 h incubation at -20°C, an aliquot was
used for protein determination, and then 350 μg of pro-
teins were centrifuged 15 min at 300 × g. The pellet was air
dried and then dissolved in 7 M urea, 2 M thiourea
(Sigma-Aldrich), 4% CHAPS (Sigma-Aldrich), 0.8% IPG
buffer (Amersham Biosciences, Qc, Canada), bromophe-
nol blue, and 10 mg/ml dithiothreitol (DTT). Denatured
proteins were first separated according to their isoelectric
point using 13 cm Immobiline DryStrip with a pH range
of 3–10 with IPGphor isoelectric focusing system (Amer-
sham Biosciences). Isoelectric focusing was done in four
steps: re-hydration at 30 V for 10 h; 500 V for 1 h; 1,000 V
for 1 h, and; 8,000 V to reach 17,500 Vh final. After these
steps, strips were equilibrated 15 min in 50 mM Tris-HCl,
6 M urea, 30% (vol/vol) glycerol, 2% (wt/vol) SDS, and
bromophenol blue. Then, each strip (total of two strips;
samples were run in duplicate) was loaded on a 12% SDS-
PAGE. After migration, proteins of one gel were silver
stained while proteins of the second gel were transferred
to a nitrocellulose membrane and 17βHSD2 protein was
detected with our anti-17βHSD2 antibody as described
above.
Immunohistochemistry
Tissue sections were deparaffinized in xylene and rehy-
drated through graded ethanol. Tissue sections were incu-
bated in 3% hydrogen peroxide in methanol for 30 min to
block endogenous peroxidase activity and rinsed in dis-
tilled water. Antigen retrieval was carried out in sodium
citrate buffer (0.1 M citric acid, 0.1 M sodium citrate) by
boiling slides in a microwave oven for 2 min at maximum
power and then cooling down at room temperature.
Slides were rinsed once in distilled water for 5 min and
once in PBS for 5 min before the blocking step. Unspecific
binding was blocked by incubation of tissue sections in
10% goat serum in PBS containing 0,1% BSA and 0,4%
Triton X-100 for 30 min. The tissue sections were then
incubated with primary antibodies overnight at 4°C in a
humidified chamber. The anti-17βHSD2 antibody was
used at 1:200 dilution, the anti-KDR (Chemicon Interna-
tionnal, Temecula, CA) was used at 1:50 dilution. KDR/
VEGF-R2 (Vascular endothelial growth factor – Receptor
2) was used as an endothelial cell marker. Expression of
KDR decreases as pregnancy progress and becomes barely
detectable near term. Following the incubation with the
primary antibody, the slides were washed 3 times in PBS
and incubated with biotinylated goat anti-rabbit (Dako-
Cytomation Inc. Mississauga, Ontario, Canada) for
17βHSD2 and goat anti-mouse (Chemicon International
Inc., Mississauga, Ontario, Canada) for KDR for 45 min at
room temperature. The slides were washed 3 times in PBS
and the antigen-antibody complex was revealed using avi-
din-biotin peroxidase reaction method using the ABC
Vectastain kit (Vector Laboratories, Inc., Burlingame, CA)
and AEC (3-Amino-9-ethylcarbazole) as chromagen. The
immunoreactivity was visualized as red color. Control
experiments for the 17βHSD2 were performed on adja-
cent sections by substitution of the antibody by the pre-
immune rabbit serum or by the 17βHSD2 antibody
adsorbed with an excess (10-6 M) of the synthetic peptide
instead of primary antibody. Anti-KDR control experi-
ments were performed by replacing the primary antibody
with 0.01 M PBS.
Immunohistochemistry quantification
Quantification of 17βHSD2 signal in different parts of
mid-gestation and term placentas were performed using a
Zeiss Axioskop 2 Plus microscope linked to a digital cam-
era (Spot Insight, Carsen Medical Scientific, Markham,
ON, Canada) using Image Pro-Plus software (Carsen
Medical Scientific). Red staining intensities in IIV and SV
from mid-gestation placentas or SV and TV from term pla-
centas were quantified as follows using Image Pro-Plus.
Briefly, IIV, SV or TV were delimitated using the "New
AOI" command. The created areas of interest were meas-
ured using measurement commands. The "Select Color"
command was used to specify the range of intensities/
colors that defined the section analysed. The selected
range color was applied for each measurement. The ratio
of the mean intensity/density values was calculated for
each type of villi from the same slide. Twenty-three IIV
and 17 SV structures were analysed from 13 mid-gestationReproductive Biology and Endocrinology 2007, 5:30 http://www.rbej.com/content/5/1/30
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placentas. For the analyses on term placenta, 10 TV and 9
SV structures were analysed from 5 placentas.
In situ hybridization
Synthesis of RNA probes and in situ hybridization were
performed as described previously [18,33] with minor
modifications. Briefly, RNA probes were synthesized from
the 303 bp Eco RV fragment of 17βHSD2 [34] inserted
into pSV-SPORT-1. After linearization of the plasmid
DNAs by Bam HI and Xho I, antisense and sense 17βHSD2
RNA probes were synthesized using (35S)-UTP (NEN Life
Science Products, Boston, MA). Probes were synthesized
using the Riboprobe Combination System kit (Promega
Corp., Madison, WI), and riboprobes with less than 1.4 ×
109 dpm/μg DNA matrix were discarded. After deparaffin-
ization and re-hydration, tissue sections were fixed in 4%
paraformaldehyde (Sigma, St-Louis, Missouri USA) for 20
min, treated with proteinase K (10 μg/ml; Sigma) for 25
min at 37°C, acetylated in 37.5 mM triethanolamine
solution (Sigma) containing 0.25% (vol/vol) anhydric
acid (Sigma) for 10 min, dehydrated in graded alcohol
solutions, and air-dried. Hybridization (2 × 106 dpm/100
μl/slide) was performed overnight at 58°C in 50% forma-
mide, 0.3 M NaCl, 10 mM Tris-HCl (pH 8.0), 1 mM
EDTA, 1× Denhardt's (100× = 2% BSA, 2% polyvinylpyr-
rolidone, and 2% Ficoll), 1% dextran sulphate, 10 mM
DTT, and 500 μg/ml transfer RNA. After hybridization,
slides were treated with ribonuclease A for 30 min and
washed under high stringency conditions in 0.1× SSC
(Standard Saline Citrate) and 1 mM DTT at 58°C for 30
min. After defatting, tissues were coated with NTB-2 emul-
sion (Eastman Kodak Co., Rochester, NY) and kept at 4°C
for 5 to 10 days. Slides were developed with D-19 solution
(Eastman Kodak Co.), counterstained with 0.25% thio-
nine (Sigma), dehydrated, and mounted with Permount
(Fisher Scientific).
Western blot analysis of 17βHSD2 protein in human term 
placenta and in mid-late secretory phase endometrial 
tissue
Placental and endometrial tissues were homogenized in
ice-cold buffer containing 10% SDS, 10 mM Tris-HCL pH
7.5, 1 mM DTT and 1 mM PMSF. Proteins were precipi-
tated with methanol-chloroform, solubilized in SDS-
PAGE sample buffer containing 1% SDS, 62.5 mM Tris-
HCL pH 6.8, 1% 2-mercaptoethanol, 10% glycerol and
0.025% bromophenol blue, heated at 95°C for 3 min
then stored at -20°C until use. Protein concentration of
samples was determined by BCA protein assay after pre-
cipitation with trichloro acetic acid. 50 μg of endometrial
proteins and 50, 2.5, 1.0, 0.5, 0.25, and 0.1 μg of placental
proteins were separated by SDS-PAGE and transferred to a
nitrocellulose membrane (Bio-RAD) for Western blot
analysis. Membranes were treated as described above.
After washing, bound antibodies were revealed by chemi-
luminescence with horseradish peroxidase-conjugated
goat anti-rabbit IgG antibodies using a SuperSignal West-
Dura kit (incubation 5 min) and Kodak XAR films (expo-
sition 30 sec).
Measurement of testosterone, estrone and estradiol in 
human term placenta and in mid-late secretory phase 
endometrial tissue
Steroid hormones were extracted as follows. Frozen tis-
sues (200 mg) were pulverized, weighed, and transferred
into glass tubes. After suspension in 0.5 ml PBS pH 7.0, 1
ml of ethanol:acetone (1:1, v:v) was added. Samples were
homogenized and centrifuged to pellet tissue debris.
Supernatants were exposed to nitrogen gas flow to remove
organic solvents and the volumes were measured by a gas
chromatographic mass spectrometric method developed
to measure steroid hormone levels in rat and monkey sera
[35]. Briefly, steroids were extracted from PBS by liquiq-
liquid and solid-phase extraction. Derivatization reac-
tions were performed to improve chromatographic and
detection responses. Testosterone, estrone and estradiol
were quantified by gas chromatography and negative
chemical ionization mass spectrometry (GC/MS) as
reported [35].
Statistical analysis
Statistical analyses were performed usingt-test function of
GraphPad Prism 3.0 (GraphPad Software, San Diego, CA)
and SPSS 10.0.5 softwares (SPSS, Chicago, IL). A two-
tailed p value of less than 0.05 was considered a signifi-
cant difference.
Results
Levels of 17βHSD2 mRNA in different sections of the 
human term placenta
17βHSD2 mRNA levels were determined by Northern
blot analysis in 5 samples of villi collected at different
positions relative to the insertion point of the umbilical
cord. Two placentas obtained at term pregnancy were
studied. 17βHSD2 mRNA levels in placental samples are
quite similar, and independent from the sampling site
(Figure 1).
Levels of 17βHSD2 mRNA in human placenta during 
pregnancy
17βHSD2 mRNA levels were determined by real-time PCR
in 25 samples obtained between gestation weeks 15 and
24 6/7 and in 10 samples obtained at term (38–41
weeks). No significant variation was observed in the
expression of the 17βHSD2 among samples collected
around mid-gestation (Figure 2). However, a 2.27 fold
increase was observed in the group of samples collected at
term when compared to the group of samples collected at
mid-pregnancy. No difference in 17βHSD2 mRNA expres-Reproductive Biology and Endocrinology 2007, 5:30 http://www.rbej.com/content/5/1/30
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sion according to foetal sex was observed (data not
shown).
Characterization of the anti-17β-HSD2 polyclonal 
antibody
The specificity of our novel anti-17βHSD2 polyclonal
antibody was evaluated by Western blot, two-dimen-
sional gel electrophoresis, and immunohistochemistry. In
Western blot, a single positive signal of Mr 42000 was
detected in placental microsome cell fraction but not in
cytosol, as expected for 17βHSD2 [14] (Figure 3A). There
was no signal when pre-immune serum was used instead
of the antibody (Figure 3B) or when the antibody was first
adsorbed with an excess of the 17βHSD2 synthetic
polypeptide (Figure 3C). Finally, only one positive signal
was detected with this antibody from a microsomal frac-
tion of placenta resolved by two-dimensional gel electro-
phoresis (Figure 3D and 3E). Immunohistochemistry was
also performed on endometrial tissue and the staining
was specific to glandular epithelial cells of the secretory
endometrium, as reported previously [29] (data not
shown). We conclude that our antibody specifically
detects the 17βHSD2 protein.
Immunohistochemistry of 17βHSD2 and KDR in human 
placenta at mid-gestation
At mid-gestation, the placenta is mainly composed of
mesenchymal villi (MV), immature intermediate villi
(IIV) and stem villi (SV). These three types of villi are
shown in Figure 4A. Early in pregnancy (10 weeks),
17βHSD2 was easily detected in mesenchymal cells of the
MV (Figure 4D). At mid-gestation, a majority of cells com-
posing the stroma in the MV were 17βHSD2-positive (Fig-
ure 4A). In the IIV, staining for 17βHSD2 was very strong
and uniform (Figure 4A). The stroma of the IIV is com-
posed of longitudinally oriented stromal channels (SC)
(Figure 4C), and immunoreactivity was observed in the
majority of the cells composing the channel's periphery.
In the IIV, several capillaries are present, particularly
beneath the syncytial layer. The endothelial cells of the
foetal capillaries in the IIV strongly expressed the
17βHSD2. When the IIV is transformed into SV, the tran-
sition begins with a stromal fibrosis starting around a cen-
trally positioned foetal vessel [24]. The SV at mid-
gestation is mainly composed of 1 or 2 central foetal ves-
sels and a paravascular capillary network (PC) beneath
the syncytial layer (Figure 4A). The staining for 17βHSD2
was very strong in endothelial cells of the capillaries form-
ing the PC. Endothelial cells of the foetal vessels (EC) also
expressed the 17βHSD2. Cells forming the PC network in
SV showed a positive signal for KDR (Figure 4G). In IIV,
both endothelial cells of the capillary network and cells
composing the wall of stromal channel were immunos-
tained by the anti-KDR (Figure 4H).
Immunohistochemistry of 17βHSD2 in human term 
placenta
At term, the placental villi is mainly composed of terminal
villi (TV) and stem villi (SV). TV is the most abundant type
of villi at term, with more than 50% of its stromal volume
occupied by the foetal capillaries. All these capillaries
strongly expressed the 17βHSD2. Again, the syncytium
was negative. In the SV (Figure 5D and 5E), 17βHSD2 was
localized in endothelial cells of the foetal blood vessels
and in capillaries composing the PC. However, some large
blood vessels were clearly and strongly positive for
17βHSD2 (EC+), while others showed a signal close to the
background (EC-) (Figure 5D).
Localization of 17βHSD2 mRNA in mid-gestation and term 
placenta by in situ hybridization
In mid-gestation placentas, 17βHSD2 mRNA was abun-
dant in the IIV and in the PC network of the SV (Figure 6A
and 6C). The mRNA was also detected in endothelial cells
of large blood vessels in SV (Figure 6D). At term, in situ
hybridization revealed that 17βHSD2 mRNA was abun-
dant in TV (data not shown). This result concurs with that
obtained by immunohistochemistry (Figures 4 and 5). In
the SV, expression of the 17βHSD2 gene was detected in
endothelial cells of several large blood vessels (EC+). As
observed in immunohistochemistry experiments, the
staining in some vessels was close to the background (EC-
).
Northern blot analysis of five samples of villous tissue col- lected at different positions relative to the insertion point of  the umbilical cord using 20 μg of total RNA loaded in each  lane Figure 1
Northern blot analysis of five samples of villous tissue col-
lected at different positions relative to the insertion point of 
the umbilical cord using 20 μg of total RNA loaded in each 
lane. Blots were probed with 17βHSD2 and actin cDNAs. 
Two placentas obtained at term were studied. Autoradio-
grams for Northern blots were densitometrically scanned 
and no significant variation between samples was observed.Reproductive Biology and Endocrinology 2007, 5:30 http://www.rbej.com/content/5/1/30
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Quantitative evaluation of 17βHSD2 
immunohistochemistry staining
Quantification of 17βHSD2 staining using the Image-Pro
Plus software showed that in mid-gestation placenta,
17βHSD2 was more abundant in the IIV than in the SV
and that in term placenta, 17βHSD2 was more abundant
in the TV than in the SV (Figure 7).
Estrone, estradiol and testosterone levels, and 17βHSD2 
mRNA and protein levels in term placenta and mid-late 
secretory phase endometrial tissue
As shown in Table 1, estrogens levels measured in term
placenta are much higher than in endometrial tissue. Also,
in term placenta, level of testosterone is very low when
compared to those of E1 and E2. However, in both tissues,
E1 and E2 levels are quite similar. We also compared
mRNA and protein levels of 17βHSD2 between term pla-
centa and endometrium. 17βHSD2 mRNA level, as deter-
mined by QPCR, and 17βHSD2 protein level, as
determined by Western blot, were respectively 25.4 fold
and 30 to 60 fold higher in the placenta than in the
endometrium (Table 1).
Discussion
During pregnancy, E2 plays an important role in the mat-
uration of some foetal organs such as the lungs, skin and
HPA axis [3-7,36]. However, excessive exposure to estro-
genic compounds could have deleterious consequences
on foetal development. Indeed, clinical reviews of women
who were exposed to the synthetic estrogen diethyl-
Expression of 17βHSD2 mRNA in human mid-pregnancy and term placentas Figure 2
Expression of 17βHSD2 mRNA in human mid-pregnancy and term placentas. Levels of 17βHSD2 mRNA were determined by 
real-time quantitative PCR in 35 placental tissues collected at the indicated gestation time. For each sample, 17βHSD2 expres-
sion level was normalized by a factor generated from the expression levels, in the same sample, of the three most stable house-
keeping genes studied (YWHAZ-HPRT1, and GAPDH), using the geNorm software (for details, see Methods). Means ± SD are 
presented.Reproductive Biology and Endocrinology 2007, 5:30 http://www.rbej.com/content/5/1/30
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Characterization of the anti-17βHSD2 antibody Figure 3
Characterization of the anti-17βHSD2 antibody. Western blot analysis: Cytosol and microsomes extracted from human pla-
cental villi were resolved on a 12% SDS-PAGE and transferred on nitrocellulose membrane. Immunodetection was performed 
using purified rabbit anti-17βHSD2 antibody (Panel A), preimmune rabbit serum (Panel B), or antibody pre-adsorbed with an 
excess (10-6M) of 17βHSD2 synthetic polypeptide (Panel C). Specificity of the anti-17βHSD2 antibody was also studied by two-
dimensional gel electrophoresis (Panels D and E). Microsomal fraction of placental villi was separated by 2-dimensional isoelec-
tric focusing-SDS-PAGE. Panel D, silver staining. Panel E, immunodetection with the purified anti-17βHSD2 antibody. Position 
of the circle on panel D corresponds to the location of the circle on panel E. The upper arrow corresponds to a pI value of 
approximately 8 to 9 and arrow on the right side corresponds to the expected molecular weight.Reproductive Biology and Endocrinology 2007, 5:30 http://www.rbej.com/content/5/1/30
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stilbestrol showed that foetal exposure to high estrogenic
compound had adverse developmental effects and could
result in anomalies in adulthood [37-44]. Exposure in
utero to environmental components with estrogenic activ-
ity could also results in reproductive disorders [45-47].
Elevated levels of natural estrogens during gestation have
been associated with an increase in children breast or tes-
ticular cancer [48-50]. A study conducted in rat has shown
that minor elevation of E2 level in gestation can retard
foetal development or be lethal [51]. It was hypothesized
that entry of E2 in foetal circulation may be limited by
presence of 17βHSD2 in foetal endothelial cells
[18,20,22]. In support to this, E2 increase in maternal
vein during pregnancy is not accompanied by a parallel
increase in the umbilical vein, while E1 level increases
during pregnancy in the umbilical vein [9,10,12,13]. This
study of 17βHSD2 expression in placenta was designed to
assess the potential of this enzyme to act as a barrier in the
control of E2 transfer in foetal circulation during preg-
nancy.
17βHSD2 mRNA level was measured in different parts of
term placenta to evaluate if there is a spatial variation in
expression (Figure 1). Our results indicate that 17βHSD2
mRNA expression is independant of the sampling site.
Also, this supports the concept that 17βHSD2 should be
Localization of 17βHSD2 and KDR proteins in mid-gestation  placentas Figure 4
Localization of 17βHSD2 and KDR proteins in mid-gestation 
placentas. Tissue sections of human placentas obtained at 19 
weeks (Panels A and B), 18 weeks (Panel C), 10 weeks (Panel 
D) or 20 weeks (Panels E-H) of pregnancy were immunos-
tained with anti-17βHSD2 (Panels A, C-F), with pre-adsorbed 
antibody, as negative control (Panel B), or with anti-KDR 
antibody used as endothelial cell marker (Panels G and H). 
17βHSD2 protein expression is observed in immature inter-
mediate villi (IIV) (Panels A, C, E, F), in capillary endothelial 
(CE) cells and in cells forming the stromal channel (SC) (Panel 
C). Positive cells (most probably endothelial cells (EC)) were 
found in mesenchymal villi (MV). No signal was observed in 
trophoblastic sprout (TS), in syncytial layer (SL), and in 
decidua (DC) (Panel A). In stem villi (SV) (Panel A), EC of large 
blood vessels and those of paravascular capillary (PC) net-
work are positive. Endothelial cells forming PC network in 
SV (Panel G) and those composing the wall of the stromal 
channel were immunostained by the anti-KDR (Panel H). 
Intervillous space (IS), where maternal blood circulates, is 
indicated.
Localization of 17βHSD2 protein in human term placentas Figure 5
Localization of 17βHSD2 protein in human term placentas. 
Tissue sections of term placentas were immunostained with 
anti-17βHSD2 (Panels A, C-E) or with pre-adsorbed antibody, 
as negative control (Panel B). Strong positive signals were 
observed in terminal villi (TV) (Panels A and C), more pre-
cisely in sinusoidal capillaries (Si). 17βHSD2 expression is 
observed in the paravascular capillary net (PC) as well as in 
endothelial cells (EC) forming the blood vessel walls of stem 
villi (SV) (Panels D and E). Some blood vessels are EC positive 
(+) and others EC negative (-).Reproductive Biology and Endocrinology 2007, 5:30 http://www.rbej.com/content/5/1/30
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expressed at similar levels throughout placental villi to
assume an efficient role in the control of the amount of E2
secreted into foetal circulation.
We have precisely determined the level of 17βHSD2
mRNA by real-time quantitative PCR in different samples
of mid-gestation and term placentas (Figure 2). 17βHSD2
mRNA levels were quite stable between 15 and 24 weeks,
whereas 17βHSD2 mRNA levels increased by 2.27 fold
between mid-gestation (15–24 weeks) and term (38–40
weeks). The period between mid-gestation and the begin-
ning of the third trimester is an important transitional
phase in villous development [24,26], characterized by
expansion of the foetal capillary bed and branching ang-
iogenesis. Between 10–13 weeks and term, the proportion
of villous volume occupied by the capillaries increases
from 6% to 25%, the major change occurring at 23–24
weeks [52]. In contrast, the proportion of villous volume
occupied by the trophoblasts remains relatively constant
throughout pregnancy [52]. Since 17βHSD2 is expressed
in endothelial cells, the observed increase in mRNA levels
is in agreement with the developmental pattern of the pla-
cental vasculature.
We have characterized the distribution of 17βHSD2 in
placental villi at different developmental stages using
immunohistochemistry (Figures 4 and 5). Quantitative
evaluation of 17βHSD2 protein-positive staining in pla-
cental structures shows that in mid-gestation placenta,
17βHSD2 is more abundant in immature intermediate
villi (IIV) than in stem villi (SV). It also shows that at term,
17βHSD2 is more abundant in terminal villi (TV) than in
stem villi (SV) (Figure 7). By in situ hybridization, strong
signals were obtained in both mid-gestation IIV and term
TV (Figure 6). In the mid-gestation mesenchymal villi
(MV), the majority of cells composing the stroma were
positive for 17βHSD2 (Figure 4). MV is the forerunner of
all types of villi and is transformed into IIV at mid-preg-
nancy [24]. This transition is characterized by an
expanded loose stroma and an increase in capillary den-
sity due to branching angiogenesis [26]. IIV is the prevail-
ing villous type until the end of the second trimester [24].
In IIV, 17βHSD2 is very abundant in the majority of cells
forming the edge of the stromal channel, and in cells
forming the capillary network (Figure 4). The enzyme is
also present in endothelial foetal capillary cells. At mid-
gestation, cells forming the edge of the stromal channels
express several angiogenic factors like vascular endothelial
growth factor-A (VEGF-A), angiopoietin-1, and angiopoi-
etin-2 [53] that are involved in the development and
remodelling of placental vasculature [26,54]. Also, it was
reported that KDR (VEGF-R2) is expressed by endothelial
Quantitative evaluation of 17βHSD2 protein expression in  immature intermediate villi (IIV) and stem villi (SV) of human  mid-gestation placentas and from terminal villi (TV) and stem  villi (SV) of human term placentas Figure 7
Quantitative evaluation of 17βHSD2 protein expression in 
immature intermediate villi (IIV) and stem villi (SV) of human 
mid-gestation placentas and from terminal villi (TV) and stem 
villi (SV) of human term placentas. Twenty-three IIV and 17 
SV structures were analysed from 13 mid-gestation placen-
tas, while 10 TV and 9 SV structures were analysed from 5 
term placentas. Quantification of immunohistochemical stain-
ings was performed using a Zeiss Axioskop 2 plus miscro-
scope linked to a digital camera (Spot Insight; Carsen Medical 
Scientific, Markham, ON, Canada) using Image Pro software 
analysis (Carsen Medical Scientific). *: p < 0.001.
Localization of 17βHSD2 mRNA in human mid-pregnancy  and term placentas Figure 6
Localization of 17βHSD2 mRNA in human mid-pregnancy 
and term placentas. In situ hybridization was performed with 
antisense (Panels A, C and D) and sense (negative control, 
Panel B) RNA probes on tissue sections of placentas obtained 
at 18 weeks of gestation (Panels A, B, and C), or at term (Panel 
D). Emulsion granules (positive signals) appear as white dots 
on darkfields. SV, stem villi; IIV, immature intermediate villi: 
SL, syncytial layer; PC, paravascular capillary net; EC+ and 
EC-, endothelial cells with, respectively, positive and negative 
signal with the 17βHSD2 antisense probe.Reproductive Biology and Endocrinology 2007, 5:30 http://www.rbej.com/content/5/1/30
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cells of foetal vessels and by endothelial cell precursors
[55]. KDR was also localized in cytotrophoblasts [56]. We
observed a correlation between 17βHSD2 and KDR stain-
ings (Figures 4E and 4G, and 4F and 4H), thus suggesting
that positive cells in the stroma of MV and IIV should be
endothelial cells or endothelial cell precursors. It is inter-
esting to note the presence of KDR in cytotrophoblasts,
while no staining was detected for 17βHSD2 in those
cells. In SV, staining for 17βHSD2 was very strong in
endothelial cells of PC network underneath the syncytial
layer, and in endothelial cells of mature venules and arte-
rioles. However, the stroma was negative. In term pla-
centa, 17βHSD2 is strongly expressed in the numerous
foetal capillaries of TV (Figure 5), which is the most effec-
tive structure for foeto-maternal exchanges. Indeed, capil-
laries make up more than 50% of its stromal volume. Our
results show that in both mid-gestation and term pla-
centa, 17βHSD2 protein is concentrated in structures were
exchanges between the mother and the foetus are the
most effective.
With respect to E2 inactivation, it is interesting to com-
pare 17βHSD2 mRNA and protein, and steroid levels
between the placenta and the endometrium. In
endometrium, 17βHSD2 is expressed in glandular epithe-
lial cells during the mid to late secretory phase [17,29].
Several studies showed that 17βHSD2 is absent in secre-
tory endometriotic tissues [17,28,29]. The absence of
17βHSD2 expression favors the increasing quantities of
E2 observed in endometriosis [17,29]. We show that lev-
els of 17βHSD2 mRNA and protein are 25.4 and 30 to 60
fold higher, respectively, in term villi than in mid-late
secretory phase endometrium (Table 1), thus supporting
an important capacity of E2 inactivation by the placenta.
As also shown in Table 1, the placental tissue contains
much higher levels of estrogens than endometrial tissue.
However, the levels of E1 and E2 were similar in each tis-
sue, suggesting that 17βHSD2 favors equilibrium between
inactive and active forms of estrogens, and that elevated
levels of E2 in placenta do not overwhelm the inactivating
capacity of the enzyme. Also, the measured levels of testo-
sterone (T) and E2 in term placenta are 1.57 ng/g and
39.66 ng/g, respectively, suggesting that E2 is the principal
substrate of 17βHSD2, since both steroids have a similar
affinity for the enzyme. Taken together, these observa-
tions support the concept that levels of 17βHSD2 in the
human placenta are sufficient to yield significant rates of
conversion of E2 into E1, despite the fact that placental E2
concentrations are elevated.
In conclusion, the spatial and temporal expression of
17βHSD2 mRNA and protein in the placenta during preg-
nancy and the comparison of 17βHSD2 expression and
steroid levels between term placenta and mid-late secre-
tory phase endometrium provide clear evidences that
17βHSD2 can act as a barrier to protect the foetus against
excessive E2 levels.
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